A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522553-19-00

Enrollment

Registered

2026-01-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symptomatic genetic and familial dilated cardiomyopathy.

Brief summary

Change from Baseline (Day 1) to Week 26 in left atrial function index (LAFI) in Cohort 1., Change from Baseline (Day 1) to Week 26 in peak oxygen consumption (pVO2) in Cohort 1.

Interventions

DRUGPlacebo tablets contain the same excipients as Danicamtiv tablets except the active substance.

DRUGDanicamtiv

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from Baseline (Day 1) to Week 26 in left atrial function index (LAFI) in Cohort 1., Change from Baseline (Day 1) to Week 26 in peak oxygen consumption (pVO2) in Cohort 1.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026